Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

Y0000440

Didanosine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2′,3′-Dideoxyinosine, ddI, ddIno

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C10H12N4O3
CAS Number:
Molecular Weight:
236.23
Beilstein/REAXYS Number:
3619529
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

didanosine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23

InChI

1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

InChI key

BXZVVICBKDXVGW-NKWVEPMBSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Didanosine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Masiá et al.
International journal of STD & AIDS, 16(9), 646-648 (2005-09-24)
The combination of tenofovir and didanosine results in an increase in the didanosine plasma exposure and might augment the risk for didanosine toxicity. Although pharmacokinetic studies support a didanosine dose reduction to 250 mg when used concurrently with tenofovir in
Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature.
J C Lederman et al.
The American journal of gastroenterology, 96(12), 3474-3475 (2002-01-05)
C M Perry et al.
Drugs, 58(6), 1099-1135 (2000-01-29)
Didanosine, like zidovudine, stavudine and lamivudine, is a nucleoside analogue reverse transcriptase inhibitor (NRTI). In the target cell for HIV, didanosine is converted to its active moiety, dideoxyadenosine-5'-triphosphate (ddATP), which inhibits HIV reverse transcriptase and terminates viral DNA growth. It
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
R J De Boer et al.
AIDS (London, England), 12(13), 1567-1570 (1998-10-09)
Hui-Min Chang et al.
Japanese journal of infectious diseases, 65(1), 61-65 (2012-01-26)
Noncirrhotic portal hypertension (NCPH) has recently been reported as a liver complication in human immunodeficiency virus (HIV)-infected patients and has been found to be associated with exposure to didanosine. Here, we describe the case of an HIV-infected patient with portal

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service